Eli Lilly and : Our 2024 Sustainability Report PDF (2024 SustainabilityReport Final)
LLY
Published on 07/11/2025 at 09:29
2024
Sustainability Report
Table of Contents
A Message from Our CEO 3
Sustainability Highlights 4
Our Strategy
Our Sustainability Strategy 6
Stakeholder Engagement and Topic Identification 8
Our Sustainability Goals 9
Environmental
Our Environmental Approach 11
Climate 12
Waste 18
Water 24
Product Stewardship 28
Biodiversity 33
Social
Our Social Approach 36
U.S. Access & Affordability 37
Global Access & Health 44
Our Sustainability site always contains the latest information about our sustainability strategy, goals, progress and data.
This file is provided as an archive of Lilly's 2024 Sustainability Report.
Community Engagement 51
Inclusion on Purpose 55
Employee Experience 57
Human Rights 64
Patient Safety 68
Governance
Our Governance Approach 72
Business Ethics 72
Corporate Governance 78
Supply Chain Management 82
Transparency
Transparency 87
SASB Index 87
SDGs 91
TCFD 94
UNGC Index 94
Reports & Policies 96
About Our Sustainability Report 97
A Message from Our CEO
David A. Ricks Chair and CEO
To Our Stakeholders:
For nearly 150 years, Lilly has been at the forefront of creating breakthrough medicines that improve human health. Our most profound global impact is reflected in the millions of people who benefit from our medicines each year.
Key to our progress on behalf of patients is our longstanding commitment to sustainability, as we work to strengthen communities, responsibly steward natural resources, and empower our global workforce. We continue to pursue ambitious, measurable sustainability goals, which are embedded in our business strategy and operations. Highlights in 2024 include:
Advancing toward our 2030 climate goals of being carbon neutral in our own operations and purchasing all our electricity from renewable sources. In 2024, we secured 58% of our purchased electricity from renewable sources and reduced our Scope 1 and 2 greenhouse gas emissions by 37% from 2020 to 2024, while our overall business has grown.
Implementing a new on-site solar array at our corporate headquarters in Indianapolis, with on-site solar present at Lilly facilities in eight countries.
Reaching an estimated 58 million people with our medicines in 2024.
As part of our goal to improve healthcare for 30 million people in resource-limited settings by 2030, we reached 24 million people in 2024.
Providing $4.2 billion in medicines in 2024 to charitable organizations that offer medicines at no cost to qualifying patients around the world. This included more than $30.9 million in medicines to humanitarian organizations that support disaster preparedness, disaster relief and humanitarian aid.
Introducing LillyDirect®, a direct-to-consumer digital healthcare experience for patients in the U.S., expanding access to millions of adults with obesity, diabetes and migraine.
Guided by our values of integrity, excellence, and respect for people, we will continue to tackle the most critical medical challenges in ways that transform human health and make a lasting contribution to humanity.
We appreciate your interest in our work and support of our progress.
Sincerely,
David A. Ricks Chair and CEO
See important information about our Sustainability Report.
My signature above affirms our company's ongoing commitment and our intent to support and advance the United Nations Global Compact's ten universally accepted principles in the areas of human rights, labor, environment, and anti-corruption, in addition to the United Nations Sustainable Development Goals.
Sustainability Highlights
Introduced LillyDirect®, a direct-to-consumer digital healthcare experience for patients in the U.S., expanding access to millions of adults with obesity, diabetes and migraine directly from a secure, trusted source
Partnered with EVA Pharma to expand access to insulin and baricitinib in Africa
Donated $6.5 million to the U.S. Fund for UNICEF to enhance health outcomes for
at-risk children and youth in resource-limited settings in India
$4.2 Billion in Free Medicines Provided in 2024, including
$30.9 million in disaster relief and humanitarian assistance1
Reduced Scope 1 and 2 Greenhouse Gas
Emissions by 37% from
2020 to 2024, while our overall business has grown
Purchased 58% of our purchased electricity from renewable sources in 2024, doubling our renewable energy purchasing compared to 2023
KEY NOTES
1. Includes value of medicines provided by Lilly and its affiliates to charitable organizations that offer free Lilly medicines to qualifying patients. Product donations valued at wholesale acquisition cost.
Recognitions
At Lilly, we strive to make life better for our own workforce, for people touched by our medicines, and the communities in which we operate. We've received recognition from several distinguished organizations for our efforts.
See our recent recognitions.
Our Strategy
IN THIS SECTION
Our Sustainability Strategy 6
Stakeholder Engagement
and Topic Identification 8
Our Sustainability Goals 9
Download Data Sheet
Disclaimer
Eli Lilly and Company published this content on July 11, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 11, 2025 at 13:28 UTC.